- Home
- NBIX vs IPG Comparison
NBIX vs IPG Comparison
Compare NBIX & IPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- IPG
- Stock Information
- Founded
- NBIX 1992
- IPG 1902
- Country
- NBIX United States
- IPG United States
- Employees
- NBIX N/A
- IPG N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- IPG Advertising
- Sector
- NBIX Health Care
- IPG Consumer Discretionary
- Exchange
- NBIX Nasdaq
- IPG Nasdaq
- Market Cap
- NBIX 11.0B
- IPG 8.9B
- IPO Year
- NBIX 1996
- IPG N/A
- Fundamental
- Price
- NBIX $115.71
- IPG $25.11
- Analyst Decision
- NBIX Strong Buy
- IPG Buy
- Analyst Count
- NBIX 20
- IPG 9
- Target Price
- NBIX $163.20
- IPG $33.22
- AVG Volume (30 Days)
- NBIX 1.9M
- IPG 4.5M
- Earning Date
- NBIX 05-05-2025
- IPG 04-24-2025
- Dividend Yield
- NBIX N/A
- IPG 5.25%
- EPS Growth
- NBIX N/A
- IPG N/A
- EPS
- NBIX 2.96
- IPG 1.31
- Revenue
- NBIX $2,412,600,000.00
- IPG $9,001,000,000.00
- Revenue This Year
- NBIX $15.36
- IPG N/A
- Revenue Next Year
- NBIX $16.34
- IPG $2.78
- P/E Ratio
- NBIX $39.13
- IPG $19.11
- Revenue Growth
- NBIX 21.73
- IPG N/A
- 52 Week Low
- NBIX $84.23
- IPG $22.51
- 52 Week High
- NBIX $157.98
- IPG $33.05
- Technical
- Relative Strength Index (RSI)
- NBIX 60.88
- IPG 50.64
- Support Level
- NBIX $105.45
- IPG $24.80
- Resistance Level
- NBIX $130.46
- IPG $25.62
- Average True Range (ATR)
- NBIX 4.31
- IPG 0.56
- MACD
- NBIX 1.96
- IPG 0.14
- Stochastic Oscillator
- NBIX 50.22
- IPG 74.63
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About IPG Interpublic Group of Companies Inc. (The)
Interpublic Group is among the world's largest advertising holding companies based on annual revenue. It provides traditional advertising services along with digital and other services such as public relations through various acquisitions. IPG has made these services available in over 100 countries. The company generates about 65% of revenue in the US and 17% in the UK and Europe. IPG agreed to merge with Omnicom in December 2024, pending regulatory approval.